Skip to main content
Professional Technical IVT

MEN2

Also written as: MEN2 — multiple endocrine neoplasia type 2

Multiple endocrine neoplasia type 2, an inherited syndrome predisposing to medullary thyroid carcinoma and pheochromocytoma.

Full Definition

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant hereditary cancer syndrome caused by germline mutations in the RET proto-oncogene. MEN2 is subdivided into MEN2A and MEN2B, both characterized by predisposition to medullary thyroid carcinoma. MEN2A also includes pheochromocytoma and parathyroid adenomas, while MEN2B includes pheochromocytoma, mucosal neuromas, and marfanoid habitus. Genetic testing for RET mutations is crucial for family screening, and prophylactic thyroidectomy timing is determined by specific mutation risk stratification. Regular biochemical surveillance for catecholamines and calcitonin is essential in mutation carriers.

Usage

Usage note: Distinguish MEN2A from MEN2B by clinical features; always specify subtype when known.

In Context

  • "Genetic testing revealed a RET mutation consistent with MEN2A syndrome." — Genetics consultation note
  • "Prophylactic thyroidectomy was recommended at age 5 given the high-risk MEN2B mutation." — Pediatric endocrinology note

Also known as

multiple endocrine neoplasia type 2

Don't confuse with

MEN1 MEN4 familial medullary thyroid carcinoma

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON